Journal articles on the topic 'Skin Cancer Victoria'
To see the other types of publications on this topic, follow the link: Skin Cancer Victoria.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 17 journal articles for your research on the topic 'Skin Cancer Victoria.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Shih, S., R. Carter, S. Heward, and C. Sinclair. "Costs Related to Skin Cancer Prevention in Victoria and Australia." Journal of Global Oncology 4, Supplement 2 (October 1, 2018): 9s. http://dx.doi.org/10.1200/jgo.18.10800.
Full textAbstract:
Background: The aim of this presentation is to provide an update on the economic evaluation of the Australian SunSmart program as well as outline the cost of skin cancer treatment to the Victorian public hospital system. This follows the publication of two recently released published economic evaluations that discusses the potential effects of skin cancer prevention inventions. Aim: 1. To highlight the cost effectiveness of skin cancer prevention in Australia 2. To highlight the costs of skin cancer treatment in the Victorian public hospital system 3. To provide strong evidence to inform governments of the value of skin cancer prevention to reduce the costs of treatment in future years. Methods: Program cost was compared with cost savings to determine the investment return of the program. In a separate study, a prevalence-based cost approach was undertaken in public hospitals in Victoria. Costs were estimated for inpatient admissions, using state service statistics, and outpatient services based on attendance at three hospitals in 2012-13. Cost-effectiveness for prevention was estimated from 'observed vs expected' analysis, together with program expenditure data. Results: With additional $AUD 0.16 ($USD 0.12) per capita investment into skin cancer prevention across Australia from 2011 to 2030, an upgraded SunSmart Program would prevent 45,000 melanoma and 95,000 NMSC cases. Potential savings in future healthcare costs were estimated at $200 million, while productivity gains were significant. A future upgraded SunSmart Program was predicted to be cost-saving from the funder perspective, with an investment return of $3.20 for every additional dollar the Australian governments/funding bodies invested into the program. In relation to the costs to the Victorian public hospital system, total annual costs were $48 million to $56 million. Skin cancer treatment in public hospitals ($9.20∼$10.39 per head/year) was 30-times current public funding in skin cancer prevention ($0.37 per head/year). Conclusion: The study demonstrates the strong economic credentials of the SunSmart Program, with a strong economic rationale for increased investment. Increased funding for skin cancer prevention must be kept high on the public health agenda. This would also have the dual benefit of enabling hospitals to redirect resources to nonpreventable conditions.
2
Lanzer, Daniel. "Skin and Cancer Foundation of Victoria Dermatologic Surgery Meeting August 1993." Australasian Journal of Dermatology 34, no. 3 (December 1993): 135–36. http://dx.doi.org/10.1111/j.1440-0960.1993.tb00887.x.
Full text
3
Montague, Meg, Ron Borland, and Craig Sinclair. "Slip! Slop! Slap! and SunSmart, 1980-2000: Skin Cancer Control and 20 Years of Population-Based Campaigning." Health Education & Behavior 28, no. 3 (June 2001): 290–305. http://dx.doi.org/10.1177/109019810102800304.
Full textAbstract:
The Anti-Cancer Council of Victoria has been running sun protection programs for more than 20 years: Slip! Slop! Slap! from 1980 to 1988 and SunSmart from 1988 to the present. The Victorian Health Promotion Foundation has provided funding for the SunSmart program for the past 13 years. These programs have played an important role in changing the whole society’s approach to the sun and have resulted in marked reductions in sun exposure. This article describes the social, political, economic, and organizational context within which these programs developed. Then 10 areas are discussed that illustrate a critical aspect of the development and implementation of this successful systemwide health promotion program. These areas focus on key aspects of the context within which the program operates and on issues that derive from the experience of implementing program strategies. In summary, the success of the two programs is described as having been built on two key foundations: the vital integration of research and evaluation, on one hand, and a strong basis of consistency and continuity, on the other.
4
Sinclair, C., S. Dobbinson, and M. Montague. "Can a Skin Cancer Control Program make a Difference? A Profile of the SUNSMART Programme in Victoria." Radiation Protection Dosimetry 91, no. 1 (September 2, 2000): 301–2. http://dx.doi.org/10.1093/oxfordjournals.rpd.a033224.
Full text
5
Biondi, Christine, Vivienne Milch, Van Nguyen, Regina Ryan, David Roder, Alan Woods, Kristie Cooper, Rhona Wang, Cleola Anderiesz, and Dorothy Mary Kate Keefe. "The COVID-19 pandemic led to a reduction in cancer services in Australia." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e18812-e18812. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e18812.
Full textAbstract:
e18812 Background: Australian oncologists reported dramatic decreases in cancer referrals during the pandemic. As real time data were difficult to acquire, Cancer Australia used surrogate measures to infer where reductions in medical services occurred. We analysed data available through the Medicare Benefits Schedule (MBS), a list of the medical services and professional attendances subsidised by the Australian Government, for the five highest incidence cancers: breast, colorectal, lung, prostate, and skin cancers. Methods: We identified over 500 MBS item codes for diagnostic and treatment procedures for malignancies and pre-cancerous conditions. Item codes were categorised into analysis groups based on cancer type and/or similarities in type of service. Data were examined at national and jurisdictional levels for 2020 to determine reductions during the initial COVID-19 period and to monitor subsequent recovery. Data were compared to 2019 to account for normal seasonal variation. Results: Australia’s first wave of the pandemic ran from March to May, and a second wave in the state of Victoria alone ran from July to September 2020. We observed notable reductions across all diagnostic and surgical procedure groups examined, with initial reductions observed between March and April for diagnostic procedures, and a one-month delay for surgical procedures, between April and May. Some services showed an initial recovery in May, with many showing partial or full recovery by June. For some groups, analyses showed sustained reductions over the 12-month period. While COVID-19 case numbers were greater during the second wave, the impact on services was less pronounced, likely owing to more refined policy approaches to managing health system and workforce capacity. There was further recovery by September for some but not all services. Similar patterns of change were observed across all Australian states and territories, with some variation by jurisdiction. Conclusions: The pandemic has impacted the delivery of cancer care. Any potential delays in diagnoses and treatment due to these reductions in services may lead to more advanced cancer stage at diagnosis and poorer patient outcomes including recurrence and survival. Impact of COVID-19 on selected cancer services in Australia in 2020.[Table: see text]
6
Fleming, Julia Ann, and Bradley David O’Connor. "Use of Lidocaine Patches for Neuropathic Pain in a Comprehensive Cancer Centre." Pain Research and Management 14, no. 5 (2009): 381–88. http://dx.doi.org/10.1155/2009/723179.
Full textAbstract:
BACKGROUND: There are few reports of the use of the lidocaine 5% patch (L5%P) for neuropathic pain (NP) in the cancer patient. Within a comprehensive cancer centre, L5%P has been prescribed by the Pain and Palliative Care Service (Peter McCallum Cancer Centre, East Melbourne, Victoria, Australia) for selected patients with NP since 2001.OBJECTIVE: To retrospectively audit the use of L5%P within a comprehensive cancer centre.METHODS: All L5%P prescriptions up to January 2009 were listed and patient medical records were searched to determine neuropathic pain syndromes treated, the presence of allodynia, previous analgesic medications, treatment duration and outcome.RESULTS: L5%P was prescribed for 97 patients, most frequently for persistent postsurgical NP (n=26), postherpetic neuralgia (n=24) and cancer-related NP (n=18). Six patients had no history of cancer and two patients never applied L5%P. Reviewers classed L5%P analgesic efficacy as ‘potent’ in 38% of patients with postherpetic neuralgia, 35% of patients with postsurgical pain, 27% of patients with NP after other treatments for cancer and 12% of patients with NP attributed to cancer alone. Allodynia featured in at least 60% of patients. Where allodynia was present, the efficacy of L5%P was assessed as ‘potent’ in 38% and ‘partial’ in 24%, but ‘ineffective’ in 26%, and ‘causing worse pain’ in 3.4% of patients. Treatment duration extended longer than one month in 52 patients, longer than two months in 29 patients and longer than one year in 13 patients. Therapy was ceased due to skin irritation in seven patients. The outcomes in relation to other reports are discussed.CONCLUSION: The present data support trials of L5%P for cancer patients with NP syndromes associated with allodynia.
7
Liu, Bing, Shu-Fang Jin, Hua-Chao Li, Xiang-Yu Sun, Si-Qi Yan, Shu-Jun Deng, and Ping Zhao. "The Bio-Safety Concerns of Three Domestic Temporary Hair Dye Molecules: Fuchsin Basic, Victoria Blue B and Basic Red 2." Molecules 24, no. 9 (May 5, 2019): 1744. http://dx.doi.org/10.3390/molecules24091744.
Full textAbstract:
Hair-coloring products include permanent, semi-permanent and temporary dyes that vary by chemical formulation and are distinguished mainly by how long they last. Domestic temporary hair dyes, such as fuchsin basic, basic red 2 and Victoria blue B, are especially popular because of their cheapness and facile applications. Despite numerous studies on the relationship between permanent hair dyes and disease, there are few studies addressing whether these domestic temporary hair dyes are associated with an increased cancer risk. Herein, to ascertain the bio-safety of these temporary hair dyes, we comparatively studied their percutaneous absorption, hemolytic effect and cytotoxic effects in this paper. Furthermore, to better understand the risk of these dyes after penetrating the skin, experimental and theoretical studies were carried out examining the interactions between the dyes and serum albumins as well as calf thymus (CT)-DNA. The results showed that these domestic temporary hair dyes are cytotoxic with regard to human red blood cells and NIH/3T3 cell lines, due to intense interactions with bovine serum albumin (BSA)/DNA. We conclude that the temporary hair dyes may have risk to human health, and those who use them should be aware of their potential toxic effects.
8
Doss, Victoria, Erin Healy, Sasha Beyer, Sachin R. Jhawar, Jose G. Bazan, and Julia White. "Abstract P3-19-17: Radiation of the low axilla in the prone position." Cancer Research 82, no. 4_Supplement (February 15, 2022): P3–19–17—P3–19–17. http://dx.doi.org/10.1158/1538-7445.sabcs21-p3-19-17.
Full textAbstract:
Abstract Background: Whole breast irradiation (WBI) after a positive sentinel lymph node biopsy (SNB) is recommended to be treated in the supine position to facilitate inclusion of the low axilla with “high tangents” when regional nodal irradiation is not planned. Treatment in the prone position has several advantages over supine positioning including minimizing heart and lung doses for many and decreased skin toxicity for larger breasted women. We hypothesized that, using three dimensional conformal radiation therapy (3DCRT), the low axilla can be safely and adequately treated in the prone position with minimal toxicity and good outcomes. Methods: We identified patients who underwent post lumpectomy whole breast and low axilla irradiation in the prone position using 3DCRT from 2014 to 2020. Standard 3DCRT treatment planning included delineation of surgical cavity, breast and low axillary clinical target volumes (CTV) with 5 mm expansion to planning target volumes (PTV). The “low axilla” CTV was generally defined as the level I axilla according to the RTOG Breast Cancer Atlas. Dosimetric data for both targets and organs at risk (OARs) was extracted from approved treatment plans’ dose-volume histograms (DVHs). Toxicity and cancer outcomes were collected from the electronic medical records. Descriptive statistical analysis was performed. Results: Seventy patients were identified. Median age was 61 years (range 34-87), median body mass index (BMI) was 30.4 kg/m2 (range 22.1-49.1), and 88.6% (N=62) had hormone sensitive, HER2 negative breast cancer. The median tumor size was 1.35 cm (range 0.07-4.5cm). For 56 patients (80.0%), a SNB was done with median of 2 (range 1-7) sentinel nodes removed - 19 (34%) with macro-metastasis (median size 4 mm, range 2.2-13mm), 21 (37.5%) with micrometastasis, and 16 (28.6%) with isolated tumor cells. Three patients had an additional node with isolated tumor cells. Thirteen (18.6%) were Nx (no nodal evaluation) and 1 had an unsuccessful SLNB with no lymph nodes obtained. Hypofractionation was used in 97.1% (N=68): 4256 cGy in 16 fractions (N=44, 62.8%) or 4000 cGy in 15 fractions (N=24, 34.3%). All targets were covered adequately. The median V95/V90 of the PTVbreast_eval, PTVlump_eval, and PTVAx were 96%/98.3% (range 76.2/91.9% - 99.6/101.4%), 100.1%/101.2% (range 87.6/94.9%-102.8/103.3%), and 95.3%/97.5% (range 82.4/91.6%-100.4/101.7%) respectively. The mean heart dose for all patients was 83.5 cGy; 82.7 cGy for right-sided tumors and 83.8 cGy for left-sided tumors. The median V16 of the ipsilateral lung was 4.25% (range 0.2 - 11.3%). Overall, toxicity was low with no grade 3 or higher events. For acute toxicity, most patients (N=54, 77.1%) reported grade 1 fatigue and had either grade 1 (N=52, 74.2%) or grade 2 (N=15, 21.4%) dermatitis. For late toxicity, 14 patients (20%) were referred to physical therapy after radiation, 7 (10%) for range of motion, 5 (7%) for arm lymphedema evaluation and 4 (6%) for other reasons. With a median follow-up of 18.5 months (range 0-63 months), 1 patient recurred both locally and regionally (1.4%) and one other patient recurred distantly. Conclusions: Patients with a positive SNB or are Nx who are recommended to have post-lumpectomy whole breast and low axilla irradiation can be safely and adequately treated in the prone position using 3DCRT with minimal toxicity and good outcomes. Citation Format: Victoria Doss, Erin Healy, Sasha Beyer, Sachin R. Jhawar, Jose G. Bazan, Julia White. Radiation of the low axilla in the prone position [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-19-17.
9
Perera, Eshini, Neiraja Gnaneswaran, Marlon Perera, and Rodney Sinclair. "Validating the use of Medicare Australia billing data to examine trends in skin cancer." F1000Research 4 (November 24, 2015): 1341. http://dx.doi.org/10.12688/f1000research.7161.1.
Full textAbstract:
Background: Epidemiological data surrounding non-melanomatous skin cancer (NMSC) is highly variable, in part due to the lack of government cancer registries. Several studies employ the use of Medical Australia (MA) rebate data in assessing such trends, the validity of which has not been studied in the past. Conversely, melanoma skin cancer is a notifiable disease, and thus, MA and cancer registry data is readily available. The aim of the current study is to assess the use of MA for epidemiological measures for skin cancers, by using melanoma as a disease sample.Methods: Following ethics approval, data from MA and Victorian Cancer Registry (VCR) from 2004-2008 were extracted. Incidence of MA and VCR unique melanoma cases were compared and stratified by age and local government area (LGA). Regression and a paired-samples t-test were performed.Results:During the study period; 15,150 and 13,886 unique melanoma patients were identified through VCR and MA data sources respectively. An outlier in the >80 year age group was noted between MA and VCR data. When stratified by age, significant correlation between MA and VCR was observed for all patients (gradient 0.91,R²= 0.936) and following exclusion of >80 patients (gradient 0.96,R²= 0.995). When stratified by LGA, a high degree of observation was observed for all patients (gradient 0.94,R²= 0.977) and following exclusion of >80 patients (gradient 0.996,R²= 0.975).Conclusion:Despite the inclusion of outlier data groups, acceptable correlation between MA and VCR melanoma data was observed, suggesting that MA may be suitable for assessing epidemiological trends. Such principals may be used to validate the use of MA data for similar calculations assessing NMSC trends.
10
Raymond, W., D. Preen, H. Keen, C. Inderjeeth, and J. Nossent. "POS0769 CANCER DEVELOPMENT IN PATIENTS HOSPITALISED WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A LONGITUDINAL, POPULATION-LEVEL DATA LINKAGE STUDY." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 671.2–671. http://dx.doi.org/10.1136/annrheumdis-2022-eular.3999.
Full textAbstract:
BackgroundThe association between systemic lupus erythematosus (SLE) and cancer risk is unclear.ObjectivesDescribe the association between systemic lupus erythematosus (SLE) and the risk of cancer development and subsequent 5-year mortality in Western Australia (WA).MethodsPopulation-level cohort study of SLE patients (n=2,111) and general population comparators (n=21,110) hospitalised between 1980–2014. SLE patients (identified by ICD-9-CM: 695.4, 710.0, and ICD-10-AM: L93.0, M32.0) were nearest matched (10:1) for age, sex, Aboriginality, and temporality. Follow-up was from timezero (index SLE hospitalisation) to cancer development, death or 31/12/2014. Using longitudinal linked health data, we determined the risk of cancer development and subsequent 5-year mortality between SLE patients and comparators with Cox proportional hazards regression models.ResultsSLE patients had similar multivariate-adjusted risk (aHR 1.03, 95%CI 0.93, 1.15; P=0.583) of cancer development. Cancer development risk was higher in SLE patients <40 years old (aHR 1.51), and from 1980-1999 (aHR 1.28). SLE patients had higher risk of developing cancer of the oropharynx (aHR 2.13); vulvo-vagina (aHR 3.22); skin (aHR 1.20), and, lymphatic and haematopoietic tissues (aHR 1.78), all P<0.05. SLE patients had reduced risk of breast cancer (aHR 0.64). After cancer development, SLE patients had increased risk of 5-year mortality (aHR 1.16, 95%CI 1.01, 1.33); highest in 40-49 years old (aHR 1.89), and in those with skin (aHR 1.65) or prostate cancer (aHR 4.74).ConclusionHospitalised SLE patients had increased risk of multiple cancers, but a reduced risk of breast cancer. Following cancer development, SLE patients had increased risk of 5-year mortality. Together there is scope to improve cancer prevention and surveillance in SLE patients.AcknowledgementsThe authors wish to thank the staff at the Western Australian Data Linkage Branch and Emergency Department Data Collection, Hospital Morbidity Data Collection, Western Australian Cancer Registry, and Death Registrations. The authors wish to thank the Australian Co-ordinating Registry, the Registries of Births, Deaths and Marriages, the Coroners, the National Coronial Information System and the Victorian Department of Justice and Community Safety for enabling COD URF data to be used for this publication.Disclosure of InterestsNone declared
11
Ng, Jonathan C., Simon Cumming, Vivian Leung, and Alvin H. Chong. "Accrual of non-melanoma skin cancer in renal-transplant recipients: Experience of a Victorian tertiary referral institution." Australasian Journal of Dermatology 55, no. 1 (June 28, 2013): 43–48. http://dx.doi.org/10.1111/ajd.12072.
Full text
12
Felmingham, Claire, Gabrielle Byars, Simon Cumming, Jane Brack, Zongyuan Ge, Samantha MacNamara, Martin Haskett, Rory Wolfe, and Victoria Mar. "Testing Artificial Intelligence Algorithms in the Real World: Lessons From the SMARTI Trial." Iproceedings 8, no. 1 (March 1, 2022): e36902. http://dx.doi.org/10.2196/36902.
Full textAbstract:
Background A number of studies have shown promising performance of artificial intelligence (AI) algorithms for diagnosis of lesions in skin cancer. To date, none of these have assessed algorithm performance in the real-world setting. Objective The aim of this project is to evaluate practical issues of implementing a convolutional neural network developed by MoleMap Ltd and Monash University eResearch in the clinical setting. Methods Participants were recruited from the Alfred Hospital and Skin Health Institute, Melbourne, Australia, from November 1, 2019, to May 30, 2021. Any skin lesions of concern and at least two additional lesions were imaged using a proprietary dermoscopic camera. Images were uploaded directly to the study database by the research nurse via a custom interface installed on a clinic laptop. Doctors recorded their diagnosis and management plan for each lesion in real time. A pre-post study design was used. In the preintervention period, participating doctors were blinded to AI lesion assessment. An interim safety analysis for AI accuracy was then performed. In the postintervention period, the AI algorithm classified lesions as benign, malignant, or uncertain after the doctors’ initial assessment had been made. Doctors then had the opportunity to record an updated diagnosis and management plan. After discussing the AI diagnosis with the patient, a final management plan was agreed upon. Results Participants at both sites were high risk (for example, having a history of melanoma or being transplant recipients). 743 lesions were imaged in 214 participants. In total, 28 dermatology trainees and 17 consultant dermatologists provided diagnoses and management decisions, and 3 experienced teledermatologists provided remote assessments. A dedicated research nurse was essential to oversee study processes, maintain study documents, and assist with clinical workflow. In cases where AI algorithm and consultant dermatologist diagnoses were discordant, participant anxiety was an important factor in the final agreed management plan to biopsy or not. Conclusions Although AI algorithms are likely to be of most use in the primary care setting, higher event rates in specialist settings are important for the initial assessment of algorithm safety and accuracy. This study highlighted the importance of considering workflow issues and doctor-patient-AI interactions prior to larger-scale trials in community-based practices. Acknowledgments This research was supported by the Victorian Medical Research Acceleration Fund, with 1:1 contribution from MoleMap Ltd. VM is supported by the National Health and Medical Research Council Early Career Fellowship. CF is supported by the Monash University Research Training Program Scholarship. Conflicts of Interest SM is head of clinical research and regulatory affairs at Kahu.ai Ltd, a subsidiary of MoleMap Ltd. MH was the chief medical officer and a director of MoleMap Ltd, and holds shares in MoleMap Ltd. Trial Registration ClinicalTrials.gov NCT04040114; https://clinicaltrials.gov/ct2/show/NCT04040114
13
Glenister, Kristen, Sophie Witherspoon, and Alan Crouch. "A qualitative descriptive study of a novel nurse-led skin cancer screening model in rural Australia." BMC Health Services Research 22, no. 1 (August 10, 2022). http://dx.doi.org/10.1186/s12913-022-08411-6.
Full textAbstract:
Abstract Background People residing in rural areas have higher rates of skin cancer and face barriers to accessing care. Models of skin cancer care addressing the specific needs of rural communities and overcoming specific challenges are required, but literature is scarce. This study aimed to describe the elements of a nurse-led skin cancer model in rural Victoria using qualitative methodology and programme logic to inform implementation and ongoing sustainability. Methods Qualitative descriptive design. Semi-structured interviews were conducted with key stakeholders involved in the skin cancer model, namely health service executive management, clinical staff, and administration staff. Interviews were audio-recorded and transcribed verbatim. Transcripts were thematically analysed independently by two researchers before themes were compared and refined. A programme logic model was developed to organise themes into contextual elements, inputs, activities and anticipated outcomes; it was also used as a visual tool to aid discussions with key stakeholders. Member checking of the logic model occurred to verify interpretation. This programme logic model will be refined throughout the implementation phase, and again after three years of service delivery. Results Eight stakeholders participated in interviews. Thematic analysis identified three major themes: the influence of the local rural context, the elements of the model, and “making it happen’. These major themes and accompanying sub-themes were mapped to the programme logic model by contextual elements (rural locale, health service access barriers, burden of disease), key inputs (promotion, human resources including appropriate nurse training and leadership) and ‘making it happen’ (governance including referral pathways, flexible and sustained funding, and partnerships). The anticipated outcomes identified include skin cancer care delivered locally, timely access, career development for nurses, and decreased skin cancer burden. Conclusion An initiative that is place-based and community driven in response to consumer demand addresses key system barriers to earlier detection of skin cancers. It is anticipated to result in flow-on reductions in skin cancer disease burden. Programme logic was useful to both describe the initiative and as a visual tool for discussions, with the potential to inform wider health service efforts to address system barriers and bottlenecks.
14
So, Chi, Damien McCarthy, Caroline G. Watts, Chris Kearney, Gillian Reyes-Marcelino, David E. Goldsbury, Kirstie Mcloughlin, Jon Emery, and Anne E. Cust. "Diagnostic biopsies of suspected skin cancer in general practice from 2010 to 2017 in Victoria, Australia." British Journal of Dermatology, December 22, 2022. http://dx.doi.org/10.1093/bjd/ljac111.
Full text
15
Glenister, Kristen, Mary Bougoulias, Janice Zgibor, Lisa Bourke, and David Simmons. "Self‐reported skin cancer‐related behaviours in rural Victoria: results from repeat cross‐sectional studies in 2001–2003 and 2016–2018." Australian and New Zealand Journal of Public Health, March 3, 2022. http://dx.doi.org/10.1111/1753-6405.13215.
Full text
16
Chung, Eun-Jae, Damir Matic, Kevin Fung, S. Danielle MacNeil, Anthony C. Nichols, Ruba Kiwan, KengYeow Tay, and John Yoo. "Bell’s palsy misdiagnosis: characteristics of occult tumors causing facial paralysis." Journal of Otolaryngology - Head & Neck Surgery 51, no. 1 (October 18, 2022). http://dx.doi.org/10.1186/s40463-022-00591-9.
Full textAbstract:
Abstract Objective The aim of this study was to report the incidence and clinical course of a series of patients who were misdiagnosed with Bell’s palsy and were eventually proven to have occult neoplasms. Methods Two hundred forty patients with unilateral facial paralysis who were assessed at the facial nerve reanimation clinic, Victoria Hospital, London Health Science Centre, from 2008 through 2017 were reviewed. Persistent paralysis without recovery was the presenting complaint. Results Nine patients (3.8%) who were proven to have occult neoplasms initially presented with a diagnosis of Bell’s palsy. The mean diagnostic delay was 43.5 months. Four patients were proven to have skin cancers, 3 patients had parotid cancers, and 2 patients had facial nerve schwannomas as a final diagnosis. Initial magnetic resonance imaging (MRI) was performed in all 9 patients and 8 underwent a follow-up MRI. An occult tumor was identified upon review of the original MRI in one patient and at follow-up MRI in 8 patients. The mean time interval between the initial and follow-up imaging was 30.8 months. The disease status at most recent follow-up were no evidence of disease in 2 patients (22%) and alive with disease in 7 patients (78%). An irreversible, progressive pattern of facial paralysis combined with pain, multiple cranial neuropathies or history of skin cancer were predictable risk factors for occult tumors. Seven out of the 9 patients (77.8%) underwent at least one type of facial reanimation surgery, and the final subjective results by the surgeon were available for 5 patients. Three out of the 5 (60%) patients who were available for final subjective analysis were reported as Grade III according to the modified House-Brackmann scale. Conclusion Occult facial nerve neoplasm should be suspected in patients with progressive and irreversible facial paralysis but the diagnosis may only become evident with follow-up imaging. Facial reanimation surgery is a satisfactory option for these patients. Graphical abstract
17
Jones, Shannon, Heather Walker, and Clover Maitland. "A dermoscopy training program for Victorian GPs to improve skin cancer prevention and detection." Public Health Research & Practice 32, no. 1 (2022). http://dx.doi.org/10.17061/phrp3212207.
Full text